Journal article
A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with montanide® ISA 720
JS McCarthy, J Marjason, S Elliott, P Fahey, G Bang, E Malkin, E Tierney, H Aked-Hurditch, C Adda, N Cross, JS Richards, FJI Fowkes, MJ Boyle, C Long, P Druilhe, JG Beeson, RF Anders
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2011
Abstract
Background: In a previous Phase 1/2b malaria vaccine trial testing the 3D7 isoform of the malaria vaccine candidate Merozoite surface protein 2 (MSP2), parasite densities in children were reduced by 62%. However, breakthrough parasitemias were disproportionately of the alternate dimorphic form of MSP2, the FC27 genotype. We therefore undertook a dose-escalating, double-blinded, placebo-controlled Phase 1 trial in healthy, malaria-naïve adults of MSP2-C1, a vaccine containing recombinant forms of the two families of msp2 alleles, 3D7 and FC27 (EcMSP2-3D7 and EcMSP2-FC27), formulated in equal amounts with Montanide® ISA 720 as a water-in-oil emulsion. Methodology/Principal Findings: The trial ..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
The trial was funded by PATH-MVI. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. JMC is supported by an NHMRC Practitioner Fellowship and a Queensland Health Research Fellowship. JGB was supported by a Career Development Award from the National Health and Medical Research Council, and a Future Fellowship from the Australian Research Council. Carole Long was supported in part by the intramural program of the National Institute of Allergy and Infectious Diseases, NIH. The GIA Reference Center at NIH is supported by the PATH-Malaria Vaccine Initiative.